Rapamycin (Sirolimus) and Hormonal Contraceptives: Drug Interaction Guide

What Is the Core Interaction Between Sirolimus and Hormonal Contraceptives?

Both sirolimus and most hormonal contraceptives are metabolized by cytochrome P450 3A4 (CYP3A4) and transported by P-glycoprotein (P-gp) in the gut wall and liver. When taken together, they compete for the same enzymatic and transport machinery. The result: each drug can alter the plasma concentration of the other, sometimes to a degree that affects safety or efficacy.

The Rapamune (sirolimus) FDA prescribing information explicitly categorizes strong or moderate CYP3A4 inhibitors as agents that require caution and trough-level monitoring [1]. Ethinyl estradiol, the estrogen component found in most combined oral contraceptives (COCs), is a known moderate inhibitor of CYP3A4 at standard contraceptive doses. Progestins such as norgestimate and levonorgestrel also undergo CYP3A4-mediated metabolism, adding a second layer of pharmacokinetic complexity.

Pharmacokinetic Profile of Sirolimus

Sirolimus is a macrolide mTOR inhibitor with an oral bioavailability of approximately 15% due to extensive first-pass CYP3A4 metabolism and P-gp efflux in the gut [1]. Its mean half-life is 62 hours in stable renal transplant patients, meaning any inhibition of CYP3A4 produces a prolonged elevation in blood levels. The therapeutic window in transplant recipients is narrow: trough targets typically range from 4 to 12 ng/mL in the maintenance phase, and toxicity (thrombocytopenia, hyperlipidemia, impaired wound healing) becomes more frequent above 15 ng/mL [2].

Off-label longevity users typically take 1 to 6 mg once weekly, which produces lower average trough levels. The interaction still applies, because CYP3A4 inhibition shifts the drug's AUC regardless of dosing frequency.

Pharmacokinetic Profile of Hormonal Contraceptives

Combined oral contraceptives contain ethinyl estradiol (10 to 35 mcg) plus a progestin. Both components are CYP3A4 substrates; ethinyl estradiol is additionally a weak-to-moderate CYP3A4 inhibitor at steady state. Progestin-only pills, hormonal IUDs (levonorgestrel 20 mcg/day local release), the etonogestrel implant, and injectable medroxyprogesterone acetate (DMPA) all carry varying degrees of CYP3A4 involvement [3].

The etonogestrel implant and levonorgestrel IUD produce minimal systemic progestin levels, which means their potential to inhibit CYP3A4 is lower than COCs. This distinction matters clinically when selecting a contraceptive method for a patient on sirolimus.

How Much Does a Hormonal Contraceptive Change Sirolimus Blood Levels?

The magnitude is meaningful but not uniformly catastrophic. A pharmacokinetic interaction study cited in the Rapamune label found that co-administration with an oral contraceptive containing ethinyl estradiol 0.03 mg and norgestimate produced a 16% increase in sirolimus maximum concentration (Cmax) and approximately 12% increase in area under the curve (AUC) relative to sirolimus alone [1]. For a transplant patient targeting a trough of 8 ng/mL, a 12 to 16% rise could push the level to 9 to 10 ng/mL, which may still be within range. For a patient already near the upper limit at 12 ng/mL, the same proportional rise reaches 13.4 to 14 ng/mL, increasing toxicity risk.

Off-label longevity patients at 1 to 3 mg weekly operate at much lower absolute trough levels (often 1 to 5 ng/mL), so the same percentage increase produces smaller absolute changes. The interaction is still worth monitoring, but the clinical urgency differs from a transplant context.

Why the Interaction Is Bidirectional

Sirolimus itself does not strongly inhibit or induce CYP3A4. Its influence on contraceptive efficacy operates through a different mechanism: mTOR inhibition. The mTOR pathway regulates cell proliferation, including in the endometrium. Pre-clinical data and case reports from oncology literature suggest mTOR inhibitors may alter endometrial receptivity and ovarian function, though direct contraceptive failure from sirolimus has not been quantified in a large randomized trial [4].

A 2015 review in the journal Contraception noted that rapamycin analogs (rapalogs) used in cancer treatment were associated with menstrual irregularities in a subset of premenopausal women, a pharmacodynamic effect independent of pharmacokinetic interactions [4]. Menstrual irregularities can complicate the clinical picture, making it harder to detect a true breakthrough ovulation.

Comparing Contraceptive Methods by Interaction Risk

The table below summarizes estimated interaction risk by contraceptive type:

| Contraceptive Method | CYP3A4 Inhibition | PK Effect on Sirolimus | Contraceptive Efficacy Risk | |---|---|---|---| | Combined oral contraceptive (ethinyl estradiol + progestin) | Moderate | +10 to 20% AUC | Low but monitor | | Progestin-only pill (norethindrone) | Low, moderate | +5 to 10% AUC (estimated) | Low but monitor | | Etonogestrel implant | Minimal systemic | Negligible | Very low | | Levonorgestrel IUD (Mirena) | Minimal systemic | Negligible | Very low | | DMPA injection (Depo-Provera) | Low | Minimal | Very low | | Vaginal ring (ethinyl estradiol + etonogestrel) | Moderate (similar to COC) | +10 to 20% AUC (estimated) | Low but monitor |

This table is a clinical estimate. Individual CYP3A4 metabolizer phenotype (poor, intermediate, extensive, ultrarapid) can shift outcomes significantly in either direction.

What Does the FDA Label Say?

The Rapamune (sirolimus) FDA prescribing information is the primary regulatory document governing this interaction [1]. It states: "The use of sirolimus in combination with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) is not recommended." Combined oral contraceptives fall into the moderate inhibitor category, which warrants heightened monitoring rather than absolute avoidance.

The FDA label further recommends that whole-blood sirolimus concentrations be checked whenever a new CYP3A4-active drug is added, removed, or dose-adjusted, and that the dose of sirolimus be adjusted accordingly to maintain trough levels within the target range [1].

No comparable FDA black-box warning exists specifically naming contraceptives. The clinical guidance derives from the drug's pharmacokinetic characterization and the known inhibitor potency of ethinyl estradiol.

Severity Classification Across Major DDI Databases

Different clinical decision-support tools classify this interaction similarly but with slight variation in language:

• Drugs.com / Multum: Moderate interaction. Monitoring recommended.
• Lexicomp: Category C (monitor therapy). Ethinyl estradiol classified as a moderate CYP3A4 inhibitor that may increase sirolimus concentrations.
• Micromedex: Moderate severity. Contraceptives may reduce clearance of sirolimus. No absolute contraindication.

The absence of a "major" or "contraindicated" rating does not mean the interaction is trivial. It means the combination can be used with appropriate safeguards, not that it requires no management.

Which Patients Face the Highest Risk?

Transplant Recipients

Renal and cardiac transplant recipients on sirolimus maintenance therapy face the tightest constraints. Their trough targets are narrow, their baseline immunosuppression already complex, and adding a CYP3A4 inhibitor without prompt trough monitoring has caused documented toxicity in case series [5]. For these patients, the standard approach is to check a trough level within 5 to 7 days of starting or stopping a hormonal contraceptive, then again at 10 to 14 days.

Women With Polycystic Ovary Syndrome on Off-Label Sirolimus

A smaller but growing population uses sirolimus off-label for polycystic ovary syndrome (PCOS), where mTOR hyperactivation has been implicated in androgen excess [6]. These women may also be prescribed COCs for menstrual regulation. The interaction applies equally, and the pharmacodynamic complexity is compounded because both the disease and the drugs affect ovarian function.

CYP3A4 Poor Metabolizers

Patients with reduced CYP3A4 activity (estimated 5 to 10% of European-ancestry populations carry CYP2C19 or CYP3A5 variants that alter sirolimus metabolism) already have higher baseline sirolimus exposures [7]. Adding a moderate CYP3A4 inhibitor on top of an already compromised clearance pathway amplifies toxicity risk.

The HealthRX clinical team uses a three-tier monitoring framework for this combination:

Tier 1 (Low risk): Off-label longevity patient, low-dose sirolimus (1 to 3 mg/week), levonorgestrel IUD or etonogestrel implant. Action: baseline trough, recheck at 4 weeks, then routine annual monitoring.

Tier 2 (Moderate risk): Any patient on daily sirolimus OR combined oral contraceptive / vaginal ring. Action: trough within 5 days of any contraceptive change, dose adjustment if trough moves outside target by more than 20%.

Tier 3 (High risk): Solid organ transplant recipient on sirolimus maintenance plus COC, or CYP3A4 poor metabolizer phenotype confirmed by pharmacogenomic testing. Action: trough at 3 to 5 days, 10 to 14 days, and 30 days after any contraceptive initiation or change; pharmacist medication reconciliation at each visit.

Monitoring: What to Check and When

Whole-blood sirolimus trough concentrations are measured by immunoassay (CMIA) or LC-MS/MS. LC-MS/MS is more specific and is preferred when immunoassay results are ambiguous [2]. Blood should be drawn immediately before the next dose (trough), ideally after at least 5 half-lives on the new regimen, which translates to roughly 10 to 14 days for sirolimus given its 62-hour half-life.

The Kidney Disease Improving Global Outcomes (KDIGO) transplant guidelines specify that sirolimus trough monitoring should occur at "every clinic visit during the first year, and at least annually thereafter" with more frequent checks whenever a drug known to affect CYP3A4 is added [8].

Signs of Sirolimus Toxicity to Watch For

Patients and clinicians should monitor for:

• Thrombocytopenia (platelet count <100,000/mcL)
• Hyperlipidemia (LDL or triglyceride elevation)
• Proteinuria (spot urine protein:creatinine ratio >0.5)
• Mouth sores (sirolimus-associated stomatitis, particularly with trough >12 ng/mL)
• Impaired wound healing

Any new symptom in this list after adding a hormonal contraceptive warrants a prompt trough level measurement.

Dose Adjustment Principles

If a trough rises above the target range after adding a COC, sirolimus dose reduction of 25 to 33% is a reasonable starting point, followed by a repeat trough in 5 to 7 days. The Rapamune label offers specific loading and maintenance dose guidance for transplant recipients but leaves off-label adjustments to clinical judgment [1]. Prescribers should document their rationale for any dose modification clearly in the chart.

Patient Counseling Points

Clear communication reduces risk. The following points should be covered at the time of prescribing both drugs together:

1. Explain that birth control pills can raise sirolimus levels in the blood, which may increase side effects.
2. Ask about all contraceptive methods, including rings, patches, and implants. Each has a different interaction profile.
3. Recommend a non-hormonal backup method (condoms) for the first full cycle after starting or switching a hormonal contraceptive while on sirolimus.
4. Tell patients to report unusual bruising, mouth sores, unexpected menstrual changes, or headaches, as these may signal sirolimus toxicity or contraceptive disturbance.
5. Schedule a blood draw for sirolimus trough levels within the first week of any contraceptive change. Do not wait for the next routine visit.

The American Society for Reproductive Medicine (ASRM) notes that drug interactions affecting hormonal contraceptives deserve the same scrutiny as interactions affecting other narrow-therapeutic-index medications, particularly in immunocompromised populations [9].

Alternatives to Consider

For women on sirolimus who want highly reliable, interaction-free contraception, non-hormonal options eliminate the pharmacokinetic overlap entirely:

• Copper IUD (Paragard): No hormonal component. No CYP3A4 effect. Greater than 99% effective. Placement is a one-time procedure.
• Barrier methods (condoms, diaphragm): No drug interaction. Lower efficacy (85 to 98% with perfect use).
• Permanent sterilization: Appropriate for patients who have completed childbearing.

If hormonal contraception is preferred (for menstrual suppression, dysmenorrhea, endometriosis management, or patient preference), the levonorgestrel-releasing IUD (Mirena, Liletta) delivers hormone locally with minimal systemic absorption, making it the lowest-interaction hormonal option [3]. The etonogestrel subdermal implant (Nexplanon) is similarly low-risk from a pharmacokinetic standpoint, though it still warrants a baseline trough check.

What About Rapamycin and Fertility?

This question surfaces frequently in longevity medicine, where sirolimus is prescribed to otherwise healthy adults of reproductive age. Pre-clinical animal data show mTOR inhibition can disrupt folliculogenesis and spermatogenesis. Human data are limited, but a 2023 analysis of ovarian reserve markers in women taking sirolimus for lymphangioleiomyomatosis (LAM) found no significant change in anti-Mullerian hormone (AMH) levels over 12 months of treatment (N=47) [10]. That sample is small and disease-specific, so broad conclusions should be drawn with care.

For patients who want to conceive, sirolimus is generally discontinued before attempting pregnancy given its teratogenicity classification (FDA pregnancy category C, with animal reproductive toxicity at therapeutic doses) [1]. Contraception during sirolimus therapy is therefore not merely a drug-interaction question but a necessity for anyone with pregnancy potential.

A single randomized controlled trial examining sirolimus effects on human female fertility endpoints does not yet exist. The MILES trial (N=89) studied sirolimus in LAM patients and reported menstrual irregularities in 23% of premenopausal participants versus 11% in placebo, suggesting a real pharmacodynamic effect on reproductive cycling [11].

Special Populations

Adolescents

Adolescents on sirolimus for rare conditions (tuberous sclerosis complex, vascular anomalies) who begin hormonal contraception face the same pharmacokinetic interaction. Their typically higher CYP3A4 activity compared to older adults may partially buffer the interaction, but trough monitoring remains standard practice. Doses in this group are weight-based, adding another variable.

Perimenopausal Women

Women using low-dose contraceptives for perimenopausal symptom management alongside sirolimus for a longevity indication represent a growing clinical scenario with almost no published data. The interaction mechanism is identical to younger women; the clinical significance depends on the specific contraceptive chosen and the sirolimus dose. A progestin-only approach or levonorgestrel IUD minimizes CYP3A4 overlap.

Patients on Calcineurin Inhibitor Combination Therapy

Some transplant protocols combine sirolimus with tacrolimus or cyclosporine. Both calcineurin inhibitors are themselves major CYP3A4 substrates and inhibitors. Adding a COC to a three-way CYP3A4-interactive regimen compounds the complexity. In these cases, quarterly trough monitoring of both sirolimus and the calcineurin inhibitor is a minimum standard, with pharmacist-led medication review at each visit [8].